Results 151 to 160 of about 141,477 (341)

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Time Course for Benefit and Risk of Clopidogrel and Aspirin after Acute Transient Ischemic Attack and Minor Ischemic Stroke: A Secondary Analysis from the POINT Randomized Trial.

Circulation, 2019
BACKGROUND In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial, the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage compared to ...
S. C. Johnston, J. Elm, J. D. Easton, M. Farrant, William G. Barsan, Anthony S Kim, Anne S. Lindblad, Yuko Y. Palesch, Karla G. Zurita, Gregory W. Albers, Brett L. Cucchiara, Dawn O. Kleindorfer, H. Lutsep, C. Pearson, Pramod Sethi, Nirali Vora   +15 more
semanticscholar   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction [PDF]

, 2014
Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outcomes following percutaneous coronary intervention (PCI) after non-ST elevation myocardial infarction (NSTEMI). Meta-analyses indicate that these agents are
Antoniou, S, Gallagher, S, Howard, JP, Jones, DA, Knight, C, Mathur, A, Rathod, K, Weerackody, R, Wragg, A, Wright, P   +9 more
core   +4 more sources

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel

Journal of Thrombosis and Haemostasis, 2019
Platelet P2Y12 antagonist ticagrelor reduces mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown.
A. Gąsecka, R. Nieuwland, M. Budnik, F. Dignat-George, C. Eyileten, P. Harrison, R. Lacroix, A. Leroyer, G. Opolski, Kinga Pluta, E. van der Pol, M. Postuła, P. Siljander, J. Siller-Matula, K. Filipiak   +14 more
semanticscholar   +1 more source

Immuno‐haemostatic dysregulation in heart failure with preserved ejection fraction

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex condition with partially unclear pathophysiology, in which systemic inflammation is a central contributor to changes in cardiac structure and function. The contribution of non‐traditional immune effectors—such as platelets and coagulation—remains underexplored in HFpEF ...
Giorgia D'Italia, Daniëlle M. Coenen, Titus P. Lemmens, Lloyd Brandts, Simone J. H. Wielders, Magdolna Nagy, Sanne G. J. Mourmans, Anouk Achten, Ahmad Al‐Abadi, Jerremy Weerts, Arantxa Barandiaran Aizpurua, Vanessa van Empel, Blanche Schroen, Judith M. E. M. Cosemans   +13 more
wiley   +1 more source

Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

European Journal of Heart Failure, EarlyView.
Abstract Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early ...
Antoni Bayes‐Genis, Matteo Pagnesi, Pau Codina, William T. Abraham, Offer Amir, Rudolf A. de Boer, Jasper J. Brugts, Ovidiu Chioncel, Finn Gustafsson, JoAnn Lindenfeld, Wilfried Mullens, Mark C. Petrie, Giuseppe Rosano, Marco Metra   +13 more
wiley   +1 more source

Generic versus brand-name drugs used in cardiovascular diseases [PDF]

, 2016
This meta-analysis aimed to compare the efficacy and adverse events, either serious or mild/moderate, of all generic versus brand-name cardiovascular medicines.
Boccia, Stefania, D'Andrea, Elvira, Flacco Maria, Elena, Ioannidis John, Pa, Manzoli, Lamberto, Marzuillo, Carolina, Panic, Nikola, Ricciardi, Walter, Siliquini, Roberta, Villari, Paolo   +9 more
core   +1 more source

Specific inhibition of ADP‐induced platelet aggregation by clopidogrel in vitro [PDF]

, 1999
Artur‐Aron Weber, Stephanie Reimann, Karsten Schrör   +2 more
openalex   +1 more source